Terms: = Sarcomas AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Prognosis
19 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Expression of IL-13Rα2 and FUS in glioma: clinicopathological and prognostic correlation.
Cheng G; Wang M; Zhang X; Zhang Y
BMC Neurol; 2023 May; 23(1):185. PubMed ID: 37158824
[TBL] [Abstract] [Full Text] [Related]
3. Distinct idh1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract] [Full Text] [Related]
4. Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.
Neuzillet C; Artru P; Assenat E; Edeline J; Adhoute X; Sabourin JC; Turpin A; Coriat R; Malka D
Target Oncol; 2023 Jan; 18(1):51-76. PubMed ID: 36745342
[TBL] [Abstract] [Full Text] [Related]
5. A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross W; Lyskjær I; Lesluyes T; Hargreaves S; Strobl AC; Davies C; Waise S; Hames-Fathi S; Oukrif D; Ye H; Amary F; Tirabosco R; Gerrand C; Baker T; Barnes D; Steele C; Alexandrov L; Bond G; ; Cool P; Pillay N; Van Loo P; Flanagan AM
Genome Med; 2022 Aug; 14(1):99. PubMed ID: 36042521
[TBL] [Abstract] [Full Text] [Related]
6. Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis.
Pacheco M; Barra L; Gambarotti M; Magagnoli G; Sbaraglia M; Asioli S; Cocchi S; Carretta E; Frisoni T; Benini S; Dei Tos AP; Righi A
Eur J Surg Oncol; 2022 Aug; 48(8):1730-1738. PubMed ID: 35690562
[TBL] [Abstract] [Full Text] [Related]
7. Oligosarcomas, idh-mutant are distinct and aggressive.
Suwala AK; Felix M; Friedel D; Stichel D; Schrimpf D; Hinz F; Hewer E; Schweizer L; Dohmen H; Pohl U; Staszewski O; Korshunov A; Stein M; Wongsurawat T; Cheunsuacchon P; Sathornsumetee S; Koelsche C; Turner C; Le Rhun E; Mühlebner A; Schucht P; Özduman K; Ono T; Shimizu H; Prinz M; Acker T; Herold-Mende C; Kessler T; Wick W; Capper D; Wesseling P; Sahm F; von Deimling A; Hartmann C; Reuss DE
Acta Neuropathol; 2022 Feb; 143(2):263-281. PubMed ID: 34967922
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic impact of idh mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract] [Full Text] [Related]
9. Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with idh1/2 and GNAS mutations.
Lyskjaer I; Davies C; Strobl AC; Hindley J; James S; Lalam RK; Cross W; Hide G; Rankin KS; Jeys L; Tirabosco R; Stevenson J; ; O'Donnell P; Cool P; Flanagan AM
Mol Oncol; 2021 Dec; 15(12):3679-3690. PubMed ID: 34528398
[TBL] [Abstract] [Full Text] [Related]
10. Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas CG; Grenert JP; Horvai A
Arch Pathol Lab Med; 2021 Aug; 145(8):1009-1017. PubMed ID: 33147331
[TBL] [Abstract] [Full Text] [Related]
11. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations.
Miller TI; Zoumberos NA; Johnson B; Rhodes DR; Tomlins SA; Chan MP; Andea AA; Lucas DR; McHugh JB; Smith N; Harms KL; Brewer C; Saleh J; Patel RM; Harms PW
Hum Pathol; 2020 Aug; 102():60-69. PubMed ID: 32540221
[TBL] [Abstract] [Full Text] [Related]
12. [Primary skull base chondrosarcoma: a clinicopathological analysis].
Zhang Y; Chen XN; Ren CH; Jiang CZ; Chen YP; Lin N; Wang M; Cai SS; Li GP; Zhang S; Wang XF
Zhonghua Bing Li Xue Za Zhi; 2020 Mar; 49(3):239-243. PubMed ID: 32187895
[No Abstract] [Full Text] [Related]
13. [Osteoid-forming bone tumors : Morphology and current translational cell biology].
Roessner A; Schoeder V; Smolle M; Haybäck J
Pathologe; 2020 Mar; 41(2):123-133. PubMed ID: 32078700
[TBL] [Abstract] [Full Text] [Related]
14. Future directions in soft tissue sarcoma treatment.
Hall F; Villalobos V; Wilky B
Curr Probl Cancer; 2019 Aug; 43(4):300-307. PubMed ID: 31229264
[TBL] [Abstract] [Full Text] [Related]
15. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
[TBL] [Abstract] [Full Text] [Related]
16. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Chong DQ; Zhu AX
Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149
[TBL] [Abstract] [Full Text] [Related]
17. [Classification of gliomas. Current progress and perspectives].
Capper D; Reifenberger G
Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
[TBL] [Abstract] [Full Text] [Related]
18. Papillomavirus binding factor (PBF) is an intrinsically disordered protein with potential participation in osteosarcoma genesis, in silico evidence.
Castillo P; Cetina AF; Méndez-Tenorio A; Espinoza-Fonseca LM; Barrón BL
Theor Biol Med Model; 2014 Dec; 11():51. PubMed ID: 25471943
[TBL] [Abstract] [Full Text] [Related]
19. Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through idh1/2 mutations.
Kerr DA; Lopez HU; Deshpande V; Hornicek FJ; Duan Z; Zhang Y; Rosenberg AE; Borger DR; Nielsen GP
Am J Surg Pathol; 2013 Jun; 37(6):787-95. PubMed ID: 23598960
[TBL] [Abstract] [Full Text] [Related]
